Treprostinil controlled release - Camurus

Drug Profile

Treprostinil controlled release - Camurus

Alternative Names: CAM 2043

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension

Most Recent Events

  • 26 Oct 2017 Camurus files an IND application with the US FDA for Pulmonary arterial hypertension
  • 26 Oct 2017 Camurus plans a clinical trial for Pulmonary arterial hypertension in the Q4 2017
  • 10 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top